Cytori Therapeutics (NASDAQ:CYTX) reports financial results for the quarter ended June 30, 2008. During the second quarter, there was continued demand for Cytori’s Celution® System in Europe and Asia among plastic and reconstructive surgeons. System sales in the first half of 2008 accomplished the Company’s initial goal of installing devices at key surgical centers and with luminary surgeons. Cytori anticipates significant revenue growth for the remainder of 2008, resulting from StemSource® Cell Bank orders and Celution System and related consumable sales into the European and Asia Pacific cosmetic and reconstructive surgery market. We received our first two purchase commitments for StemSource® Cell Banks during the third quarter. Based on current visibility, Cytori reaffirms its $10 to $12 million revenue guidance for 2008....
[read full story]
Your Web Site
